These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 12577460)
41. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Venerito M; Treiber G; Wex T; Kuester D; Roessner A; Di Mario F; Malfertheiner P Aliment Pharmacol Ther; 2006 Apr; 23(8):1225-33. PubMed ID: 16611284 [TBL] [Abstract][Full Text] [Related]
42. [Prevention of ulcer lesions under non-steroid antirheumatic agents. For each patient the appropriate stomach protection]. MMW Fortschr Med; 2004 May; 146(22):48. PubMed ID: 15373113 [No Abstract] [Full Text] [Related]
43. [Endoscopic changes in the stomach and duodenal mucosa caused by minidose acetylsalicylic acid therapy and their prevention]. Novotný I; Díte P; Kunovská M; Münzová H Vnitr Lek; 2007 Oct; 53(10):1053-6. PubMed ID: 18072429 [TBL] [Abstract][Full Text] [Related]
44. Protecting the stomach from the "toxins" of NSAIDS and anti-platelet agents. Echelmeyer S; Kanwal F Mo Med; 2009; 106(5):343-5. PubMed ID: 19902714 [TBL] [Abstract][Full Text] [Related]
51. NSAIDs, Cox-2 inhibitors, and the gut. Vane JR Lancet; 1995 Oct; 346(8982):1105-6. PubMed ID: 7564818 [No Abstract] [Full Text] [Related]
52. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538 [TBL] [Abstract][Full Text] [Related]
53. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Yilmaz H; Gürel S; Ozdemir O Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223 [TBL] [Abstract][Full Text] [Related]
54. [Adverse effects of nonsteroidal antirheumatic agents on the digestive tract]. Lukás M; Chalupná P; Adamec S; Bortlík M; Novotný A Sb Lek; 2002; 103(2):265-72. PubMed ID: 12688151 [TBL] [Abstract][Full Text] [Related]
55. NSAIDs, Cox-2 inhibitors, and the gut. Bennett A; Tavares IA Lancet; 1995 Oct; 346(8982):1105. PubMed ID: 7564817 [No Abstract] [Full Text] [Related]
56. [Treatment and prevention of erosive and ulcerative lesions in the stomach and duodenum caused by intake of non-steroidalanti-inflammatory drugs]. Luzina EV Klin Med (Mosk); 2014; 92(9):21-6. PubMed ID: 25790707 [TBL] [Abstract][Full Text] [Related]
57. [Physiopathology and therapy of drug-induced stomach diseases in the aged]. Asaki S Nihon Naika Gakkai Zasshi; 1995 Feb; 84(2):235-40. PubMed ID: 7722389 [No Abstract] [Full Text] [Related]
58. Cytoprotection in NSAID gastropathy. Roth SH Compr Ther; 1988 Feb; 14(2):3-5. PubMed ID: 3278837 [No Abstract] [Full Text] [Related]
60. [2-nd place of Young Scientist's Competition. Basal prostaglandins level in stomach mucous as predictors of NSAID-gastropathy]. Kim VA Eksp Klin Gastroenterol; 2009; (7):114-8. PubMed ID: 20469716 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]